Monopar Therapeutics Inc

+0.05 (+2.27%)
Earnings Announcements

Monopar Therapeutics Reports Q4 Loss Per Share $0.21

Published: 03/24/2022 12:42 GMT
Monopar Therapeutics Inc (MNPR) - Monopar Therapeutics Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Program Developments.
Q4 Loss per Share $0.21.
Monopar - Plans to Raise Funds And/or Engage Partner Within Next 12 Months to Complete Voice Clinical Program, Continue Camsirubicin Clinical Development.
Monopar-sees Current Cash Equivalents to Fund Phase 2b of Voice Trial, Commencement of Phase 3 of Voice Trial, Phase 1b Camsirubicin Trial Through at Least March 2023.
Q4 Earnings per Share View $-0.19 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.22

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.